Systemic hypertension, (high blood pressure),
affects more than 50 million adults in the United States.
Worldwide, it is one of the most common risk factors for cardiovascular
morbidity and mortality.
A randomized, double-blind, placebo-controlled clinical trial
of Coenzyme Q10 in Isolated Systolic Hypertension was recently
conducted at the Department of Veterans Affairs Medical Center
in Boise, Idaho. The conclusion reached at
the end of this twelve week study was that CoQ10 may
be safely offered to hypertensive patients as a treatment
option. The CoQ10 used in this study was our
60mg Q-Gel Ultra. |